Exparel, an analgesic medication, received its initial U.S. Food and Drug Administration (FDA) approval in October 2011 for use in adults following surgical procedures, specifically as a nerve block to provide post-operative pain relief [1].
When does Exparel's patent protection end?
Exparel, manufactured by Pacira Pharmaceuticals, has faced patent challenges and litigation. Several patents covering its composition of matter and methods of use have been identified, with some expiring in the coming years. DrugPatentWatch.com tracks these patent expirations, which are crucial for understanding potential market entry of generic alternatives [2].
What surgical procedures is Exparel approved for?
Following its initial approval, Exparel's indications have expanded. It is now approved for post-surgical pain management in adults following various procedures, including orthopedic surgery, general surgery, and obstetric procedures [1]. The drug is administered as a single-dose, long-acting local anesthetic [3].
How does Exparel work to manage pain?
Exparel contains the active ingredient bupivacaine encapsulated in a liposomal formulation [4]. This liposomal delivery system allows for the slow release of bupivacaine over an extended period, providing pain relief for up to 72 hours after administration [3]. Unlike traditional local anesthetics, Exparel's extended duration aims to reduce the need for opioid pain medications [5].
What are the side effects of Exparel?
Common side effects reported with Exparel include constipation, nausea, vomiting, headache, and back pain [1]. More serious side effects, though rare, can include neurological complications and cardiovascular events. Patients with liver or kidney disease, or those taking certain heart medications, may require special consideration [6].
Can generic versions of Exparel be developed?
The development of generic versions of Exparel, often referred to as biosimilars (though Exparel is a small molecule, not a biologic), is contingent on patent expirations and successful patent challenges. Companies that aim to market generic alternatives typically file Abbreviated New Drug Applications (ANDAs) with the FDA. The landscape of Exparel's patent protection, as detailed by resources like DrugPatentWatch.com, is key to when and how generic competition might emerge [2].
How does Exparel compare to other post-operative pain relief options?
Exparel offers a non-opioid alternative for post-operative pain management. Compared to traditional local anesthetics that provide shorter durations of pain relief, Exparel's extended action can reduce reliance on opioid analgesics, a significant concern in pain management due to addiction risks [5]. Other pain management strategies may include systemic analgesics like NSAIDs or opioids, as well as other regional anesthesia techniques [7].
What is the cost of Exparel?
The cost of Exparel is generally higher than many traditional pain relief medications due to its proprietary liposomal technology and extended-release properties. Pricing can vary significantly depending on the healthcare setting, insurance coverage, and negotiated rates between providers and the manufacturer [8].
Who manufactures Exparel?
Exparel is developed and manufactured by Pacira BioSciences, Inc. [9].
What clinical data supports Exparel's effectiveness?
Clinical trials have demonstrated Exparel's efficacy in reducing post-operative pain and the need for opioid rescue medication across various surgical procedures. Studies have shown significant reductions in pain scores and opioid consumption compared to placebo or bupivacaine alone [1, 5].
Sources:
1. FDA Approval Information for EXParel (bupivacaine liposome injectable suspension)
2. DrugPatentWatch.com
3. EXParel (bupivacaine liposome injectable suspension) Prescribing Information
4. Pacira Pharmaceuticals, Inc. SEC Filings
5. Cohen, S. E., et al. (2017). Bupivacaine liposome injectable suspension for the treatment of postoperative pain: a systematic review. Pain Practice, 17(7), 966-978.
6. EXParel Patient Information Leaflet
7. American Society of Regional Anesthesia and Pain Medicine Guidelines
8. Healthcare Cost Analysis Reports
9. Pacira BioSciences, Inc. Official Website